Engineering T cells specific for a dominant severe acute respiratory syndrome coronavirus CD8 T cell epitope

Journal of Virology

Volumn 85, Issue 20, 2011, Pages 10464-10471

  Oh, Hsueh Ling Janice ^a   Chia, Adeline ^b   Chang, Cynthia Xin Lei ^c   Leong, Hoe Nam ^d   Ling, Khoon Lin ^d   Grotenbreg, Gijsbert M ^c   Gehring, Adam J ^b   Tan, Yee Joo ^a,c   Bertoletti, Antonio ^b,c  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^b AGENCY FOR SCIENCE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HLA B ANTIGEN; HLA B40 ANTIGEN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; NUCLEOCAPSID PROTEIN; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEGRANULATION; GENE TRANSFER; HUMAN; MEMORY T LYMPHOCYTE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SARS CORONAVIRUS;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DEGRANULATION; CHEMOKINE CCL3; CHEMOKINE CCL4; EPITOPES, T-LYMPHOCYTE; GENETIC ENGINEERING; HUMANS; IMMUNODOMINANT EPITOPES; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; RECEPTORS, ANTIGEN, T-CELL; SARS VIRUS; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; CORONAVIRUS; SARS CORONAVIRUS;

EID: 80054972200     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05039-11     Document Type: Article

References (33)

1. + T cells. Blood 107:4781-4789.
2. Brochet, X., M. P. Lefranc, and V. Giudicelli. 2008. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res. 36:W503-W508.
3. + T cells are important in control of SARS-CoV infection. J. Virol. 84:1289-1301.
4. Comoli, P., et al. 2002. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 99:2592-2598.
5. Drosten, C., et al. 2003. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348:1967-1976.
6. Fan, Y. Y., et al. 2009. Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection. Arch. Virol. 154: 1093-1099.
7. Feuchtinger, T., et al. 2010. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 116: 4360-4367.
8. Gehring, A. J., et al. 2011. Engineering virus-specific T cells that target HBV-infected hepatocytes and hepatocellular carcinoma cell lines. J. Hepatol. 55:103-110.
9. Gonzalez-Galarza, F. F., S. Christmas, D. Middleton, and A. R. Jones. 2011. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res. 39:D913-D919.
10. Ksiazek, T. G., et al. 2003. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348:1953-1966.
11. Li, C. K., et al. 2008. T cell responses to whole SARS coronavirus in humans. J. Immunol. 181:5490-5500.
12. Li, T., et al. 2006. Long-term persistence of robust antibody and cytotoxic T cell responses in recovered patients infected with SARS coronavirus. PLoS One 1:e24.
13. Liu, J., et al. 2010. The membrane protein of severe acute respiratory syndrome coronavirus acts as a dominant immunogen revealed by a clustering region of novel functionally and structurally defined cytotoxic T-lymphocyte epitopes. J. Infect. Dis. 202:1171-1180.
14. Liu, S. J., et al. 2006. Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates. Vaccine 24:3100-3108.
15. Lv, Y., Z. Ruan, L. Wang, B. Ni, and Y. Wu. 2009. Identification of a novel conserved HLA-A*0201-restricted epitope from the spike protein of SARSCoV. BMC Immunol. 10:61.
16. Marra, M. A., et al. 2003. The genome sequence of the SARS-associated coronavirus. Science 300:1399-1404.
17. Peiris, J. S., K. Y. Yuen, A. D. Osterhaus, and K. Stohr. 2003. The severe acute respiratory syndrome. N. Engl. J. Med. 349:2431-2441.
18. Peng, H., et al. 2006. Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid protein in SARS-recovered patients. Virology 351:466-475.
19. + T cell responses. J. Exp. Med. 204:1405-1416.
20. Price, D. A., P. Klenerman, B. L. Booth, R. E. Phillips, and A. K. Sewell. 1999. Cytotoxic T lymphocytes, chemokines, and antiviral immunity. Immunol. Today 20:212-216.
21. + T cells exhibit multifunctional effector and helper responses, in vitro. Clin. Immunol. 136:338-347.
22. Rota, P. A., et al. 2003. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300:1394-1399.
23. Sayer, D., et al. 2001. HLA-DRB1 DNA sequencing based typing: an approach suitable for high-throughput typing including unrelated bone marrow registry donors. Tissue Antigens 57:46-54.
24. Tan, A. T., et al. 2008. Host ethnicity and virus genotype shape the hepatitis B virus-specific T-cell repertoire. J. Virol. 82:10986-10997.
25. Tsao, Y. P., et al. 2006. HLA-A*0201 T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus nucleocapsid and spike proteins. Biochem. Biophys. Res. Commun. 344:63-71.
26. Vita, R., et al. 2010. The immune epitope database 2.0. Nucleic Acids Res. 38:D854-D862.
27. + T-cell epitope SSp-1 of SARS-CoV spike protein. Blood 104:200-206.
28. Wang, Y. D., et al. 2004. T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus spike protein elicit a specific T-cell immune response in patients who recover from SARS. J. Virol. 78:5612-5618.
29. Weiss, S. R., and S. Navas-Martin. 2005. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol. Mol. Biol. Rev. 69:635-664.
30. World Health Organization. 2003. Case definitions for surveillance of severe acute respiratory syndrome (SARS). World Health Organization, Geneva, Switzerland. http://www.who.int/csr/sars/casedefinition/en/.
31. Zhang, Y., et al. 2010. Transduction of human T cells with a novel T-cell receptor confers anti-HCV reactivity. PLoS Pathog. 6:e1001018.
32. Zhao, J., and S. Perlman. 2010. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J. Virol. 84:9318-9325.
33. Zhou, M., et al. 2006. Screening and identification of severe acute respiratory syndrome-associated coronavirus-specific CTL epitopes. J. Immunol. 177: 2138-2145.